for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Koninklijke DSM N.V.

DSMN.AS

Latest Trade

189.55EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

132.70

 - 

200.00

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
189.55
Open
--
Volume
--
3M AVG Volume
7.10
Today's High
--
Today's Low
--
52 Week High
200.00
52 Week Low
132.70
Shares Out (MIL)
172.22
Market Cap (MIL)
33,349.18
Forward P/E
37.10
Dividend (Yield %)
1.26

Next Event

Full Year 2021 Koninklijke DSM NV Earnings Release

Latest Developments

More

DSM Acquires Vestkorn Milling, Valued At 65 Million Euros

DSM Receives Positive EFSA Opinion For Bovaer

DSM Q3 Adjusted EBITDA Up At 449 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Koninklijke DSM N.V.

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company's segments include Nutrition, Materials, Innovation Center and Corporate Activities. Its Nutrition segment focuses on human nutrition & health, food & beverages, personal care and aroma ingredients and animal nutrition & health. Its Materials segment engages in specialty plastics, which are used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries. Its Innovation Center segment focuses on innovation and the growth of DSM’s existing core business through adjacent technologies via its Corporate Research Program, as well as through the Company’s venturing and licensing activities. Its Corporate Activities segment comprises operating and service activities.

Industry

Food Processing

Contact Info

Het Overloon 1

6411 TE

Netherlands

+31.45.5788111

https://www.dsm.com/

Executive Leadership

Robert J. Routs

Independent Chairman of the Supervisory Board

Geraldine Matchett

Co-Chief Executive Officer, Chief Financial Officer, Member of the Management Board

Dimitri de Vreeze

Co-Chief Executive Officer, Chief Operating Officer, Member of the Management Board

Pauline van der Meer Mohr

Independent Deputy Chairman of the Supervisory Board

Eileen Kennedy

Independent Member of the Supervisory Board

Key Stats

2.31 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

9.3K

2019

9.0K

2020

8.1K

2021(E)

9.0K
EPS (EUR)

2018

5.840

2019

4.640

2020

4.120

2021(E)

5.142
Price To Earnings (TTM)
51.86
Price To Sales (TTM)
3.91
Price To Book (MRQ)
3.86
Price To Cash Flow (TTM)
27.86
Total Debt To Equity (MRQ)
36.68
LT Debt To Equity (MRQ)
35.10
Return on Investment (TTM)
4.78
Return on Equity (TTM)
3.92

Latest News

Latest News

Viewsroom: Breaking up Ant, smokes and flavors

Beijing’s crackdown on Jack Ma’s fintech giant continues, but there may be some silver linings to the latest wrinkle, Robyn Mak tells Pete Sweeney. Meantime Dasha Afanasieva explains what a cigar spinoff at Swedish Match and carveouts at Royal DSM have in common.

Top European firms back Green Deal, pledge business overhaul

Executives from 30 of Europe's leading companies backed the EU's Green Deal on Wednesday and pledged to overhaul their businesses to help the bloc achieve climate-neutrality by 2050.

BRIEF-DSM Reports Stable EBITDA For Q1, Suspends Outlook

* ADJUSTED NET PROFIT UP 8% TO EUR 216M. NET PROFIT: EUR 168M

DSM reports in-line quarterly results, suspends outlook

Dutch speciality chemicals maker DSM NV <DSMN.AS> on Thursday reported first-quarter core earnings in line with estimates, but suspended its annual outlook amid market uncertainty caused by the coronavirus crisis.

DSM to make 2.8 million nose swab coronavirus tests

Dutch nutrition and materials maker DSM NV has begun making 2.8 million nose-swab coronavirus test kits to help the Netherlands meet testing needs to manage its disease outbreak, the firm said.

BRIEF-DSM Publishes Co-CEO's Statement On Covid-19 Outbreak

* CLOSING OUR FACTORIES TO ALL NON-WORKERS AND ADDING THERMAL TESTING FOR EVERYONE ON ARRIVAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

DSM sets up vitamin E joint venture with China's Nenter

DSM NV, the Dutch nutrition company, said on Tuesday it would set up a joint venture with Chinese biochemicals company Nenter & Co. to manufacture vitamin E, paying Nenter 135 million euros ($154.45 million) to acquire its facilities in China.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up